We entered into a collaboration agreement with Kyinno Bio to co-develop a novel GPRC5D/BCMA/CD3 T-cell engager, MBS314.

We have established a strategic partnership with Betta (300558.SZ) to jointly invest in Foster Bio, a CDMO service provider. For more information, you can visit Foster Bio's website: http://www.fosterbio.com/

We have established a product commercialization partnership with Kawin (688687.SH) for its Avatrombopag Maleate tablets in designated regions. This collaboration enables us to leverage the product to enhance our own market promotion and sales network more effectively.

We grant Climb Bio (NASDAQ：CLYM）the exclusive rights to develop, manufacture and commercialize MIL116, an anti-APRIL monoclonal antibody, in the territory outside of Greater China.